Clinical trials in AD: Are current formats and outcome measures adequate?

Alzheimer Disease and Associated Disorders

Volumn 16, Issue SUPPL. 1, 2002, Pages

  Ferris, Steven H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azheimer disease; Clinical outcomes; Clinical trials; Disease progression; Primary prevention

Indexed keywords

ALZHEIMER DISEASE; DISEASE COURSE; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0036282820     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200200001-00003     Document Type: Review

References (53)

1. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease
2. Mild cognitive impairment - An early stage of Alzheimer's disease?
3. Tacrine as a treatment for Alzheimer's dementia: An interim report from the FDA
4. The search for diagnostic and progression markers in AD: So near but still too far?
5. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing
6. The biochemical aspects and CSF markers in Alzheimer's disease
7. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
8. Alzheimer's Disease International and International Working Group for Harmonization of Dementia Drug Guidelines for research involving human subjects with dementia
9. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
10. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?
11. A review of the randomised controlled trials of tacrine in the treatment of Alzheimer's disease: Methodologic considerations
12. Brain magnetic resonance spectroscopy: Role in assessing outcomes in Alzheimer's disease
13. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
14. Assessing cognition in Alzheimer disease research
15. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
16. Behavioral outcomes in clinical trials for Alzheimer disease
17. Ageing: The cholinergic hypothesis of cognitive decline
18. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis
19. Report of the European Working Group on Dementia Drug Guidelines Meeting, Brussels, November 1997
20. Quality of life in Alzheimer's disease
21. Biomarkers in Alzheimer's disease
22. Early diagnosis of Alzheimer disease with positron emission tomography
23. Age-specific incidence rates of Alzheimer's disease: The Baltimore Longitudinal Study of Aging
24. Long-term tacrine treatment effects
25. Observations and suggestions on anti-dementia drug development
26. Slowing the progression of Alzheimer disease: Methodologic issues
27. Threats to the validity of clinical trials employing enrichment strategies for sample selection
28. Rational design of an animal model for Alzheimer's disease: Introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent
29. Outcome measures for clinical trials in Alzheimer's disease: A review on some open issues
30. Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: Summary of results. The Alzheimer's Disease Cooperative Study
31. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia
32. Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia
33. Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study
34. Mild cognitive impairment: Transition between aging and Alzheimer's disease
35. Mild cognitive impairment or questionable dementia?
36. Aging, memory, and mild cognitive impairment
37. Mild cognitive impairment: Clinical characterization and outcome
38. Alzheimer's disease: Genetic studies and transgenic models
39. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease
40. The Spanish Instrument Protocol: Design and implementation of a study to evaluate treatment efficacy instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study
41. Early diagnosis of dementia: Neuroimaging
42. Transgenic approaches to model Alzheimer's disease
43. Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS)
44. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
45. Potential prevention strategies for Alzheimer disease
46. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
47. Analysis of longitudinal data in an Alzheimer's disease clinical trial
48. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: An update
49. Harmonization of dementia drug guidelines (United States and Europe): A report of The International Working Group for the Harmonization for Dementia Drug Guidelines
50. Clinical trial designs for demonstrating disease-course-altering effects in dementia
51. Magnetic resonance imaging of Alzheimer's disease